LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Handheld Device Combines Nanomaterial-Based Sensors with Neuromorphic Processor Chip to Detect SARS-CoV-2 Antibody in Seconds

By LabMedica International staff writers
Posted on 07 Apr 2021
Print article
Illustration
Illustration
A handheld device that uses nanomaterial-based sensors in combination with a neuromorphic processor chip will give accurate results for SARS-CoV-2 antibody detection in seconds.

Brainchip Research Institute (Perth, Australia), a provider of ultra-low power high performance artificial intelligence (AI) technology, has entered into a research collaboration with Biotome Pty Ltd. (Perth, Australia), a precision immunology company that is developing highly accurate antibody tests for infections.

BrainChip’s Akida neuromorphic processor chip will be used to interpret sensor responses and to find out which responses are the most representative for antibodies that are protective. The Akida chip brings AI to the edge in a way that existing technologies are not capable. The solution is high-performance, small, ultra-low power and provides a wide array of capabilities. The objective of the Biotome research project is to create a handheld device that uses nanomaterial-based sensors in combination with the Akida chip that will give accurate results in seconds. The Akida processor is an essential part of this development in its ability to learn new sensory data patterns instantly, and classify the results in milliseconds at power consumption in the microwatts range. This enables the use of advanced diagnostic equipment that operates on small batteries in even remote locations.

“We believe the precision of antibody tests for infections can be improved dramatically. Our partnership with Brainchip is an important step for our development of point-of-care tests that are based on patented high-precision immunological markers,” said Dr. Samuel Lundin, CEO of Biotome. “We are very excited to explore how the cutting-edge Akida neural processor can improve the accuracy and information quality of the antibody-tests we are developing, by providing advanced AI capacity at the point of care. The joint project we are embarking on aims to use Akida to identify the antibodies that can protect against SARS- CoV-2 infection - the so-called neutralising antibodies. If the project is successful we will apply the same principles to other antibody tests in our pipeline.”

“The use of the Akida neuromorphic processor in antibody detection and other medical diagnostic tools is a testimony to our efforts to help in the development of beneficial Artificial Intelligence applications around our chip,” said Peter van der Made, Interim CEO of BrainChip Ltd. “Our focus is the Akida neuromorphic processor, and we are a silicon manufacturer, but we are assisting our clients in bringing advanced AI products to market.”


Related Links:
Brainchip Research Institute
Biotome Pty Ltd.


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more